Klotho Neurosciences ( (KLTO)) has issued an announcement. Klotho Neurosciences, Inc. and Teleost Biopharmaceuticals, LLC have decided to end their Licensing Agreement from early 2023. This agreement ...

Klotho Neurosciences, Inc., a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to ...

Klotho Neurosciences, Inc. (NASDAQ: KLTO), is a biopharmaceutical company pioneering the development of innovative, disease-modifying cell and gene therapies using a patented secreted form of the ...

Klotho Neurosciences, Inc., a biotech company specializing in biological products, is on the brink of being delisted from the Nasdaq Stock Market. The company, which trades under the ticker KLTO ...

Appropriate levels of phosphate in the body are maintained by the coordinated regulation of the bone-derived growth factor FGF23 and the membrane-bound protein Klotho. The endocrine actions of ...

A study on kidney donors reveals persistent metabolic changes, including elevated PTH and reduced calcitriol, impacting bone ...

NEW YORK, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Klotho Neurosciences, Inc. (NASDAQ: KLTO), a cutting-edge biotechnology company focused on developing innovative therapies for neurodegenerative diseases ...

NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Klotho Neurosciences, Inc. (NASDAQ: KLTO), a U.S.-based biotechnology company pioneering cell and gene therapies for aging and age-related diseases ...